Citius Oncology (NASDAQ:CTOR) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• Citius Oncology's stock has been given a "sell (D-)" rating by Weiss Ratings, with two analysts rating it as a buy and one as a sell.
• The company's stock price increased by 3.0% to $1.72 during mid-day trading, while its target price consensus stands at $6.00.
• Institutional investors have shown significant interest, with Bank of America boosting its stake by over 5,256% during the last quarter.

Citius Oncology (NASDAQ:CTOR - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.

Other equities research analysts also recently issued reports about the company. Citigroup upgraded Citius Oncology from a "hold" rating to a "buy" rating in a research report on Tuesday, September 23rd. Maxim Group upgraded Citius Oncology from a "hold" rating to a "buy" rating and set a $6.00 target price on the stock in a research report on Tuesday, September 23rd. Finally, Wall Street Zen upgraded Citius Oncology to a "hold" rating in a research report on Saturday, July 26th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $6.00.

Citius Oncology Stock Up 3.0%

Shares of NASDAQ:CTOR traded up $0.05 during mid-day trading on Friday, reaching $1.72. The stock had a trading volume of 161,534 shares, compared to its average volume of 280,753. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.35 and a quick ratio of 0.02. Citius Oncology has a 1 year low of $0.55 and a 1 year high of $6.19. The business's 50 day moving average price is $1.85 and its 200 day moving average price is $1.73.

Institutional Investors Weigh In On Citius Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its position in Citius Oncology by 5,256.9% during the second quarter. Bank of America Corp DE now owns 8,571 shares of the company's stock valued at $37,000 after purchasing an additional 8,411 shares during the period. Arkadios Wealth Advisors purchased a new stake in Citius Oncology during the second quarter valued at approximately $51,000. Geode Capital Management LLC raised its position in Citius Oncology by 179.0% during the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company's stock valued at $249,000 after purchasing an additional 36,758 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Citius Oncology during the second quarter valued at approximately $465,000. 70.52% of the stock is currently owned by hedge funds and other institutional investors.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.